December 12, 2022 06:41 PM ESTUpdated December 13, 06:43 AM

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

FDA granted accelerated approval to Mirati’s KRAS drug adagrasib, which will be marketed as Krazati. The green light comes two days ahead of the expected …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: FDA ap­proves Mi­rati's KRAS drug in non-small cell lung can­cer

Senior Reporter

Associate Editor

Sign up to read this article for free.

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer